CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy
China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced...
HKG: 2171
CARsgen Therapeutics Partners with Jinshan Hospital for CAR-T Research
China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
CARsgen and Roche Partner on Clinical Study for Gastric Cancer Treatment
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced a clinical cooperation...
CARsgen and Huadong Medicine Partner to Commercialize BCMA CAR-T Product CT053 in China
China-based CARsgen Therapeutics Holdings Limited (HKG: 2171), a leading developer of innovative CAR T-cell therapies,...
CARsgen Develops New CAR-T Technique to Enhance Anti-Tumor Activity
China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
ASH 2022: China Biotechs Showcase Latest Clinical Trial Results
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New...
CARsgen’s BCMA-Targeted CAR-T Therapy CT053 Gains Priority Review in China
The Center for Drug Evaluation (CDE) website indicates that China-based chimeric antigen receptor (CAR)-T cell...
CARsgen Therapeutics Launches GMP Manufacturing for CAR-T Cell Therapies in North Carolina
China’s CARsgen Therapeutics Holdings Ltd (HKG: 2171), a chimeric antigen receptor (CAR)-T cell specialist, has...